Lopinavir-d8

• Description :

  Lopinavir-d8 (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].

• UNSPSC :

  12352005

• Target :

  HIV; HIV Protease; Isotope-Labeled Compounds; SARS-CoV

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease; Others

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Solubility :

  10 mM in DMSO

• Smiles :

  CC(C=CC=C1C)=C1OCC(N[C@@H](CC2=CC=CC=C2)[C@@H](O)C[C@H](CC3=CC=CC=C3)NC([C@](N4C(NCCC4)=O)([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)=O

• Molecular Formula :

  C37H40D8N4O5

• Molecular Weight :

  636.85

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Cvetkovic RS, et al. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63 (8) :769-802.|[3]Sham HL, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42 (12) :3218-3224.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1224729-35-4]